Phibro Animal Health (NASDAQ:PAHC) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other equities research analysts have also weighed in on PAHC. Zacks Investment Research lowered Phibro Animal Health from a “buy” rating to a “hold” rating in a research report on Wednesday, November 1st. Piper Jaffray Companies set a $42.00 price objective on Phibro Animal Health and gave the stock a “buy” rating in a research report on Friday, August 25th. ValuEngine lowered Phibro Animal Health from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th. Bank of America restated an “underperform” rating and set a $33.00 price objective on shares of Phibro Animal Health in a research report on Wednesday, August 23rd. Finally, Credit Suisse Group boosted their price objective on Phibro Animal Health from $36.00 to $37.00 and gave the stock an “outperform” rating in a research report on Thursday, August 31st. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $38.25.

Shares of Phibro Animal Health (NASDAQ PAHC) traded down $0.95 on Friday, hitting $33.75. The stock had a trading volume of 96,879 shares, compared to its average volume of 89,496. Phibro Animal Health has a one year low of $26.10 and a one year high of $40.25. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.85 and a current ratio of 3.26. The company has a market cap of $1,394.35, a price-to-earnings ratio of 22.68, a price-to-earnings-growth ratio of 4.07 and a beta of 1.28.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.01. Phibro Animal Health had a return on equity of 42.75% and a net margin of 8.87%. The company had revenue of $193.40 million for the quarter, compared to analyst estimates of $189.89 million. During the same quarter last year, the company posted $0.36 EPS. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. equities analysts expect that Phibro Animal Health will post 1.57 earnings per share for the current fiscal year.

In other Phibro Animal Health news, Director Gerald K. Carlson sold 5,400 shares of Phibro Animal Health stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $36.27, for a total transaction of $195,858.00. Following the transaction, the director now directly owns 5,400 shares of the company’s stock, valued at approximately $195,858. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Dean J. Warras sold 10,000 shares of Phibro Animal Health stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $35.70, for a total value of $357,000.00. Following the transaction, the insider now directly owns 10,000 shares in the company, valued at $357,000. The disclosure for this sale can be found here. Insiders have sold a total of 279,791 shares of company stock worth $10,118,331 in the last 90 days. 51.88% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in PAHC. Janus Henderson Group PLC acquired a new position in Phibro Animal Health during the 2nd quarter worth about $6,353,000. AJO LP acquired a new position in Phibro Animal Health during the 2nd quarter worth about $5,815,000. Eagle Asset Management Inc. acquired a new position in Phibro Animal Health during the 3rd quarter worth about $5,781,000. FMR LLC lifted its holdings in Phibro Animal Health by 31.9% during the 2nd quarter. FMR LLC now owns 584,463 shares of the company’s stock worth $21,654,000 after buying an additional 141,274 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Phibro Animal Health by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 1,729,406 shares of the company’s stock worth $48,597,000 after buying an additional 130,935 shares during the period. 48.42% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “BidaskClub Lowers Phibro Animal Health (PAHC) to Sell” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/02/bidaskclub-lowers-phibro-animal-health-pahc-to-sell.html.

About Phibro Animal Health

Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products.

Receive News & Ratings for Phibro Animal Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.